

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### 5-Fluoro-1-(3,4-dideoxy-3-fluoro-6-0-trityl-beta-D-glycero-hex-3-eno-pyranos-2-ulosyl (Uracil): Anticancer Agent

Abraham P. Ollapally<sup>a</sup>; Ismet Bennouna-dorange<sup>a</sup>; Thomas L. Whitaker Jr.<sup>a</sup>

<sup>a</sup> Department of Chemistry, Florida Agricultural and Mechanical University, Tallahassee, Florida

**To cite this Article** Ollapally, Abraham P. , Bennouna-dorange, Ismet and Whitaker Jr., Thomas L.(1999) '5-Fluoro-1-(3,4-dideoxy-3-fluoro-6-0-trityl-beta-D-glycero-hex-3-eno-pyranos-2-ulosyl (Uracil): Anticancer Agent', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 703 — 705

**To link to this Article:** DOI: 10.1080/15257779908041547

**URL:** <http://dx.doi.org/10.1080/15257779908041547>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**5-FLUORO-1-(3,4-DIDEOXY-3-FLUORO-6-O-TRITYL-BETA-D-GLYCERO-  
HEX-3-ENO-PYRANOS-2-ULOSYL (URACIL): ANTICANCER AGENT**

Abraham P. Ollapally,\* Ismet Bennouna-Dorange and Thomas L. Whitaker, Jr.


Department of Chemistry, Florida Agricultural and Mechanical  
University, Tallahassee, Florida 32307

**ABSTRACT:** 1,2:5,6-Di-O-isopropylidene glucofuranose on mild oxidation, reduction, fluorination and deisopropylidenation followed by acetylation gave peracetylated 3-deoxy-3-fluoro- $\alpha$ -D-glucopyranose. This was coupled with silylated 5 fluorouracil. The nucleoside was deacetylated and after several subsequent protection and deprotection and final oxidation afforded the title compound.

As an extension of our studies on ketounsaturated hexose nucleosides with 5-fluoro uracil which showed biological activity, we decided to use a fluorinated hexose to study any variation in biological activity. To this end, we first prepared the peracetylated 3-deoxy-3-fluoro- $\alpha$ -D-flucopyranose<sup>1,2</sup> **1**. This was coupled with silylated 5-fluorouracil **2**, in presence of TMS triflate to yield the protected nucleoside<sup>3</sup> **3**.

Deacetylation of **3** in methanolic ammonia gave **4** in quantitative yield. **4** was reacted with trimethylorthoformate in dry THF to protect 4',6' hydroxyls to give **5**. The protected methoxy methylene nucleoside was treated with t-butyldimethylsilyl chloride in DMF in presence of imidazole to give the completely protected nucleoside **6**. The 4',6'-methoxy methylidene protective group was cleaved in glacial acetic acid in acetone with trace of water to afford **7** which was dried well and treated with triphenyl methyl chloride in pyridine, giving the 6'-O-trityl nucleoside **8**. Acetylation of **8** under standard method gave an excellent yield of 4'-O-acetyl nucleoside **9**. On treating **9** with IM solution of tetra n-butyl ammonium fluoride in THF gave 93% yield of **10**.

Scheme



Finally, oxidation<sup>4</sup> of **10** with pyridinium dichromate in presence of molecular sieves 3Å in dry CH<sub>2</sub>Cl<sub>2</sub> gave the fluoroketo unsaturated nucleoside **11**, the target compound.

### Experimental

Melting points (uncorrected) were recorded using Mel-Temp apparatus. <sup>1</sup>H NMR spectra were recorded on a Bruker/IBM-5Y2000 spectrometer at 270 MHz with Me<sub>4</sub>Si as internal standard, <sup>19</sup>F NMR spectra were done with trifluoroacetic acid as an external standard. TLC was performed on a precoated silica gel plastic sheets 60F<sub>254</sub> (0.2 mm) EM Reagents. Compound visualization was effected with a uv lamp (254 nm) and confirmed by spraying a 5%, H<sub>2</sub>SO<sub>4</sub>/EtOH followed by heating.

#### 5-Fluoro-1-(3-deoxy-3-fluoro-2,4,6-tri-O-acetyl-β-D-glucopyranosyl) uracil **3**.

A mixture of 5-fluorouracil **2** (9.94 mmol) and saccharin 50 mg was dried with few mL of dry THF and evaporated. To this was added HMDS (11.92 mmol) and unhydr. CH<sub>3</sub>CN 20 mL, then refluxed for 3 h. The solvent was distilled to get an oily residue. A solution of **1** (8.20 mmol) in anhyd. acetonitrile (30 mL) was added to the mixture after cooling the flask to 3–4°C, followed by TMS triflate 9.44 mmol in anhyd. CH<sub>3</sub>CN (3 mL). The reaction mixture was heated at 85°C for 1 h. Cooled and then stirred overnight. Later, cooled in an ice bath, 50 mL of H<sub>2</sub>O was added and neutralized with aq. NaHCO<sub>3</sub> (10%), then extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x100 mL). The organic layer was washed with water (1x80 mL) and dried over anhydrous sodium sulphate, evaporated to dryness, finally purified by column

chromatography (silica gel) using  $\text{CH}_2\text{Cl}_2$ :MeOH (9:1) as eluent. Yield 92%, mp: 93-94°C. Anal. Calcd. for  $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_9\text{F}_2$ : C, 45.75; H, 4.28; N, 6.66. Found: C, 45.91; H, 4.09; N, 6.39. Also confirmed by NMR. Compounds **4** to **10** were confirmed by  $^1\text{H}$  NMR.

5-fluoro-1-(3,4-dideoxy-3-fluoro-6-O-trityl- $\beta$ -D-glycero-hex-3-eno-pyranos-2-ulosyl) uracil **11**. 3.0g (5.2 mmol) of **10** and 10 mmol of PDC were dried with THF. 9.0g of molecular sieves 3Å, freshly activated at 375°C was cooled and added to the flask followed by 100mL of dry  $\text{CH}_2\text{Cl}_2$  and 5 drops of glacial acetic acid. After 5 h. stirring at rt, the mixture was filtered over a bed of silica gel and washed with 0.8L of dry  $\text{CH}_2\text{Cl}_2$ . Concentrated and purified by column chromatography without applying any pressure to yield 1.22 g of **11**. 46% sirup.  $^1\text{H}$ NMR ( $\text{CH}_3\text{Cl}_3$ ):  $\delta$  8.65 (m, 1H, H-3), 7.22-7.50 (m 15H,  $3\text{C}_6\text{H}_5$ ), 6.75 (m, 1H, H-4'), 6.66 (s, 1H, H-1'), 4.12 (qd, 1H,  $J=13.7$  Hz,  $J=7.25$  Hz, H-5'), 3.55 (dd, 1H,  $J=8.0$  Hz,  $J=5.4$  Hz, H-6a'), 3.35 (dd, 1H,  $J=8.1$  Hz,  $J=5.4$  Hz H-6b').  $^{19}\text{F}$  NMR (DMSD- $d_6$ ): -90.40 - 116.35. Biological activity: showed moderate activity against Leukemias and colon cancer *in vitro*.

#### Acknowledgment

Financial support from N.I.H. (MBRS) is gratefully acknowledged.

#### REFERENCES

1. Stevens, J.D. *Methods in Carbohydr. Chem.*, VI, 123-128, Acad. Press, New York, 1966.
2. Tenson, T.J.; Welch, J.M., 1978, *J. Org. Chem.*, 43, 1090-92.
3. Sharma, A.P.; Ollapally, A.P.; Jones, W.; Lemon, T. *Nucleosides and Nucleotides*, 1992, 11, 1009-1038.
4. Herscovici, J.; Antonakis, K. *J. Chem. Soc., Chem. Commun.* 1980, 561-563.